Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPHK1 | Q9NYA1 | 11/20 | 0.36 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.36 |
| ▸ | SPHK2 | Q9NRA0 | 7/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | APP | P05067 | 1/20 | 0.33 |
| ▸ | FASN | P49327 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19829180 | 0.89 | SPHK1 (0.42) | SPHK1FFAR4SPHK2 | |
| SCHEMBL18310420 | 0.85 | CYP2C9 (0.39) | FFAR4CYP3A4CYP2C9APPFASN | |
| SCHEMBL20111086 | 0.85 | ALOX5AP (0.36) | CYP3A4CYP2C9APPFASN | |
| SCHEMBL17050138 | 0.84 | CYP3A4 (0.36) | SPHK1FFAR4SPHK2CYP3A4CYP2C9 | |
| SCHEMBL18310491 | 0.84 | FFAR4 (0.33) | FFAR4 | |
| SCHEMBL18310480 | 0.83 | CYP2C9 (0.38) | FFAR4CYP3A4CYP2C9APPFASN | |
| SCHEMBL20111088 | 0.83 | CYP2C9 (0.33) | FFAR4CYP3A4CYP2C9APPFASN | |
| SCHEMBL18310564 | 0.83 | CYP2C9 (0.38) | FFAR4CYP3A4CYP2C9APPFASN | |
| SCHEMBL18310409 | 0.83 | RARB (0.40) | — | |
| SCHEMBL18310483 | 0.83 | RARB (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9951277-B2 | Liquid crystal compound having 1,1,3,3-tetrafluoroallyloxy group, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2018-04-24 | — | — | US | disclosed |
| US-20180030351-A1 | LIQUID CRYSTAL COMPOUND HAVING POLYFLUORO-2-BUTENOXY GROUP, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2018-02-01 | — | — | US | disclosed |
| US-20160362605-A1 | LIQUID CRYSTAL COMPOUND HAVING 1,1,3,3-TETRAFLUOROALLYLOXY GROUP, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2016-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160362605-A1 | LIQUID CRYSTAL COMPOUND HAVING 1,1,3,3-TETRAFLUOROALLYLOXY GROUP, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | TCOF1, PIEZO1, RCC1 | SPHK1 3363/4885FFAR4 1281/4885SPHK2 3236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.